혈액가스 분석기 시장 예측(-2030년) : 제품 유형(소모품, 서비스), 검사 유형(PoC, 기존형), 샘플(동맥, 정맥, 모세혈관), 용도(호흡기, 응급의료 관리), 최종사용자별(병원, 진료소)

The market was valued at approximately USD 2.70 billion in 2025 and is projected to reach USD 3.38 billion by 2030, growing at a CAGR of 4.6% during the forecast period.

The market is witnessing strong growth due to the rising demand for rapid patient assessment in hospital and critical care settings, the need for continuous monitoring of acid-base balance and oxygenation in at-risk patients, and increasing healthcare spending in emerging regions. Additionally, supportive government initiatives to improve hospital diagnostic capabilities and streamline patient care further drive the adoption of blood gas analyzers worldwide.

The consumables segment accounted for the largest share of the blood gas analyzer market, by product in 2024.

The blood gas analyzer market is segmented into consumables, analyzers, and services based on product. In 2024, the consumables segment held the largest share of the market, as consumables are required for every test performed. The recurring demand for consumables in hospitals, ambulatory care settings, and clinics is a key factor driving the segment's growth.

Hospitals & ASCs segment accounted for the largest share of the blood gas analyzer market, by end user in 2024.

The blood gas analyzer market is segmented by end user into Hospitals and ASCs, Clinics, and Other End Users. In 2024, Hospitals and ASCs accounted for the largest market share, as these facilities frequently test blood gas for critically ill patients and those undergoing complex procedures. The high patient volumes and the need for continuous monitoring in these settings drive substantial demand for blood gas analyzers.

Asia Pacific is expected to be the fastest-growing region in the blood gas analyzer market.

The global blood gas analyzer market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, contributing to increased healthcare spending across a broader population base. Additional growth drivers include the rising incidence and prevalence of acute and chronic diseases, modernization of healthcare infrastructure, and the growing adoption of advanced diagnostic technologies, particularly in rural areas. These factors are anticipated to create substantial growth opportunities for blood gas analyzer companies in the Asia Pacific.

The breakup of the profile of primary participants in the blood gas analyzer market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 28%, D-level - 15%, and Others - 57%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Werfen S.A. (Spain), Nova Biomedical (US), Medica Corporation (US), Techno Medica Co., Ltd. (Japan), IDEXX Laboratories, Inc. (US), i-SENS, Inc. (South Korea), EDAN Instruments, Inc. (China), Guangzhou Wondfo Biotech Co., Ltd. (China), Labtron Equipment Ltd. (UK), Convergent Technologies GmbH & Co. KG (Germany), Erba Group (Czech Republic), ESCHWEILER GmbH & Co. KG (Germany), Sensa Core Medical Instrumentation Pvt. Ltd. (India), Chengdu Seamaty Technology Co., Ltd. (China), Labdex Ltd. (UK), Meizhou Cornley High-Tech Co., Ltd. (China), Paramedical Srl (Italy), Eaglenos Sciences, Inc. (China), B&E Bio-technology Co., Ltd. (US), Labnics Ltd. (UK) and Fison Instruments Ltd.(UK).

Research Coverage:

This research report categorizes the blood gas analyzer market by product (consumables, analyzers, and services), by type of testing (point-of-care testing and conventional testing), by sample type (arterial blood, venous blood, and capillary blood), by application (critical care management, respiratory care, emergency care management, and other applications), by end user (hospitals & ASCs, clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the blood gas analyzer market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements, product & service launches, and recent developments associated with the blood gas analyzer market. This report covers a competitive analysis of upcoming startups in the blood gas analyzer market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall blood gas analyzer market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers, such as (rising incidence and prevalence of chronic and acute conditions, advancements in blood gas analyzer technology, inadequacy of alternative techniques, growing demand for point of care blood gas analyzers), opportunities (growth opportunities in developing countries, rising ICU and emergency department admissions), restraints (unfavorable reimbursement policies, complex operations and interpretation of data), and challenges (availability of refurbished analyzers, lack of data analysis software) influencing the growth of the blood gas analyzer market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the blood gas analyzer market
• Market Development: Comprehensive information about lucrative markets-the report analyzes the blood gas analyzer market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the blood gas analyzer market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Danaher Corporation (US), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), and Siemens Healthineers AG (Germany), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 KEY STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BLOOD GAS ANALYZERS MARKET OVERVIEW
• 4.2 BLOOD GAS ANALYZERS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• 4.3 BLOOD GAS ANALYZERS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
• 4.4 BLOOD GAS ANALYZERS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 BLOOD GAS ANALYZERS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.6 BLOOD GAS ANALYZERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.7 BLOOD GAS ANALYZERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence and prevalence of chronic and acute conditions
    • 5.2.1.2 Advancements in blood gas analyzer technology
    • 5.2.1.3 Inadequacy of alternative techniques
    • 5.2.1.4 Growing demand for point-of-care blood gas analyzers
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement policies
    • 5.2.2.2 Complex operations & interpretation of data
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in developing countries
    • 5.2.3.2 Rising ICU and emergency department admissions
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Availability of refurbished analyzers
    • 5.2.4.2 Lack of data analysis software
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE TREND OF BLOOD GAS ANALYZERS, 2023-2025
  • 5.3.2 AVERAGE SELLING PRICE TREND OF BLOOD GAS ANALYZERS, BY KEY PLAYER, 2023-2025
  • 5.3.3 AVERAGE SELLING PRICE TREND OF BLOOD GAS ANALYZERS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS
  • 5.7.2 IMPORT DATA (HS CODE 9027)
  • 5.7.3 EXPORT DATA (HS CODE 9027)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 BLOOD GAS ANALYZERS MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY ANALYSIS
  • 5.10.1 REGULATORY LANDSCAPE
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
    • 5.10.1.6 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Electrochemical sensors
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Optical sensors
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Microfluidics
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: ROLE OF BLOOD GAS ANALYSIS IN EMERGENCY AND CRITICAL CARE
  • 5.16.2 CASE STUDY 2: EVALUATION OF A HANDHELD BLOOD GAS ANALYZER IN INTENSIVE CARE SETTINGS
  • 5.16.3 CASE STUDY 3: ROLE OF QUALITY MANAGEMENT SYSTEMS IN BLOOD GAS ANALYSIS
• 5.17 IMPACT OF AI/GENERATIVE AI ON BLOOD GAS ANALYZERS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI USE CASES
  • 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
  • 5.17.5 FUTURE OF AI IN BLOOD GAS ANALYZERS MARKET
• 5.18 IMPACT OF 2025 US TARIFFS ON BLOOD GAS ANALYZERS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 KEY IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & ASCs
    • 5.18.5.2 Clinics

6 BLOOD GAS ANALYZERS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 RECURRING USE OF CONSUMABLES TO DRIVE MARKET GROWTH
• 6.3 ANALYZERS
  • 6.3.1 TECHNOLOGICAL ADVANCEMENTS IN ANALYZERS TO DRIVE ADOPTION
• 6.4 SERVICES
  • 6.4.1 INCREASING FOCUS ON OPERATIONAL EFFICIENCY TO PROPEL MARKET EXPANSION

7 BLOOD GAS ANALYZERS MARKET, BY TYPE OF TESTING

• 7.1 INTRODUCTION
• 7.2 POINT-OF-CARE TESTING
  • 7.2.1 IMPROVED USABILITY AND INNOVATIONS IN POC ANALYZERS TO BOOST ADOPTION OF POINT-OF-CARE TESTING
• 7.3 CONVENTIONAL TESTING
  • 7.3.1 GROWING FOCUS ON AUTOMATION AND ACCURACY TO STRENGTHEN MARKET GROWTH

8 BLOOD GAS ANALYZERS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 ARTERIAL BLOOD
  • 8.2.1 HIGH UTILIZATION IN CRITICAL CARE SETTINGS TO SUPPORT MARKET GROWTH
• 8.3 VENOUS BLOOD
  • 8.3.1 REDUCED INVASIVENESS OF VENOUS BLOOD SAMPLING TO BOOST MARKET ADOPTION
• 8.4 CAPILLARY BLOOD
  • 8.4.1 RISING DEMAND FOR PATIENT-CENTRIC CAPILLARY SAMPLING TO DRIVE MARKET EXPANSION

9 BLOOD GAS ANALYZERS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CRITICAL CARE MANAGEMENT
  • 9.2.1 INCREASING BURDEN OF ACUTE CRITICAL ILLNESSES TO SUPPORT MARKET EXPANSION
• 9.3 RESPIRATORY CARE
  • 9.3.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET GROWTH
• 9.4 EMERGENCY CARE MANAGEMENT
  • 9.4.1 INCREASING EMERGENCY DEPARTMENT VISITS TO PROPEL DEMAND FOR BLOOD GAS ANALYZERS
• 9.5 OTHER APPLICATIONS

10 BLOOD GAS ANALYZERS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & ASCS
  • 10.2.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP MARKET GROWTH
• 10.3 CLINICS
  • 10.3.1 GROWING USE OF POINT-OF-CARE BLOOD GAS ANALYZERS TO SUPPORT MARKET GROWTH
• 10.4 OTHER END USERS

11 BLOOD GAS ANALYZERS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing prevalence of chronic & respiratory diseases to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Rising demand for real-time diagnostics tools to drive market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Favorable government policies to propel market growth
  • 11.3.3 UK
    • 11.3.3.1 Rising emergency department visits to drive market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Enhanced healthcare policies and strategic investments in diagnostics to boost market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing chronic disease incidence and government initiatives to boost Italy's blood gas analyzers market
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing public health initiatives to augment market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Healthcare infrastructure development and disease burden to support market
  • 11.4.3 JAPAN
    • 11.4.3.1 Well-developed healthcare system and high geriatric population to aid market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Initiatives to enhance access to healthcare and improve infrastructure to propel market growth
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Universal healthcare access to drive adoption in Brazil
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising medical tourism to create strong demand for advanced diagnostic solutions
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 KINGDOM OF SAUDI ARABIA
    • 11.6.2.1 Rising government healthcare expenditure to boost market
  • 11.6.3 UAE
    • 11.6.3.1 Improvements in healthcare infrastructure to support growth
  • 11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BLOOD GAS ANALYZERS MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Type of testing footprint
    • 12.5.5.5 Sample type footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 12.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 WERFEN S.A.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches
      • 13.1.2.3.2 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 SIEMENS HEALTHINEERS AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 ABBOTT LABORATORIES
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Key strengths
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 NOVA BIOMEDICAL
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 MEDICA CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
  • 13.1.8 TECHNO MEDICA CO., LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
  • 13.1.9 IDEXX LABORATORIES, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
  • 13.1.10 I-SENS, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
• 13.2 OTHER PLAYERS
  • 13.2.1 EDAN INSTRUMENTS, INC.
  • 13.2.2 GUANGZHOU WONDFO BIOTECH CO., LTD.
  • 13.2.3 LABTRON EQUIPMENT LTD.
  • 13.2.4 CONVERGENT TECHNOLOGIES GMBH & CO. KG
  • 13.2.5 ERBA GROUP
  • 13.2.6 ESCHWEILER GMBH & CO.KG
  • 13.2.7 SENSA CORE MEDICAL INSTRUMENTATION PVT. LTD.
  • 13.2.8 CHENGDU SEAMATY TECHNOLOGY CO., LTD.
  • 13.2.9 LABDEX LTD.
  • 13.2.10 MEIZHOU CORNLEY HIGH-TECH CO., LTD.
  • 13.2.11 PARAMEDICAL SRL
  • 13.2.12 EAGLENOS SCIENCES, INC.
  • 13.2.13 B&E BIO-TECHNOLOGY CO., LTD.
  • 13.2.14 LABNICS LTD.
  • 13.2.15 FISON INSTRUMENTS LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS